Visit ID : MCRL92298 Registration : 12/Mar/2024 02:22PM

UHID/MR No : ACRL.0000092298 Collected : 12/Mar/2024 02:17PM

Patient Name : Mr.AZHAR Received : 12/Mar/2024 02:47PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 12/Mar/2024 03:22PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM D Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135798

DEPARTMENT OF IMMUNOASSAY
Test Name Result Unit Bio. Ref. Range Method

TESTOSTERONE TOTAL
Sample Type : SERUM
Testosterone Total 1.70 ng/ml See the below table

Reference range
AGE MALE FEMALE
Newborn 0.75-4.00 ng/ml 0.20-0.64 ng/mL
1 - 5 months 0.14‐​3.63 ng/ml Less than 0.20 ng/mL
6-24 months Less than 0.37 ng/ml Less than 0.09 ng/mL
2‐​3 years Less than 0.15 ng/mL Less than 0.20 ng/mL
4‐​5 years Less than 0.19 ng/mL Less than 0.30 ng/mL
6-7 years Less than 0.13 ng/mL Less than 0.07 ng/mL
8-9 years 0.02-0.20 ng/mL 0.01-0.11 ng/mL
10-11 years 0.03-1.65 ng/mL 0.03-0.32 ng/mL
12-13 years 0.03-6.19 ng/mL 0.06-0.50 ng/mL
14-15 years 0.31‐​7.33 ng/mL 0.06-0.52 ng/mL
16-17 years 1.58-8.26 ng/mL 0.09 -0.58 ng/mL
18-39 years 3.00-10.80 ng/mL 0.09-0.55 ng/mL
40-59 years 3.00-8.90 ng/mL 0.09-0.55 ng/mL
60 years and older 3.00-7.20 ng/mL 0.05-0.32 ng/mL

Interpretation Testosterone is the primary male sex hormone and an anabolic steroid. In male humans, testosterone plays a key
role in the development of male reproductive tissues such as testes and prostate, as well as promoting secondary sexual
characteristics such as increased muscle and bone mass, and the growth of body hair.
It is biosynthesized in several steps from cholesterol and is converted in the liver to inactive metabolites. It exerts its action through
binding to and activation of the androgen receptor. In humans and most other vertebrates, testosterone is secreted primarily by
the testicles of males and, to a lesser extent, the ovaries of females

Clinical Use-Assessment of testicular function in males

Increased levels
Precocious puberty (Males)
Androgen resistance
Testotoxicosis

QR CODE Page 1 of 4
Visit ID : MCRL92298 Registration : 12/Mar/2024 02:22PM
UHID/MR No : ACRL.0000092298 Collected : 12/Mar/2024 02:17PM
Patient Name : Mr.AZHAR Received : 12/Mar/2024 02:47PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 12/Mar/2024 03:22PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM D Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135798

DEPARTMENT OF IMMUNOASSAY
Test Name Result Unit Bio. Ref. Range Method

Congenital Adrenal Hyperplasia

Decreased levels
Delayed puberty ( Males)
Gonadotropin deficiency
Testicular defects
Systemic diseases
Estrogen therapy
Hepatic cirrhosis

Clinical Use -Management of hirsutism & virilization in females

Increased levels
Congenital Adrenal Hyperplasia
Polycystic ovarian disease (Stein leventhal syndrome)
Ovarian tumors

QR CODE Page 2 of 4
 Visit ID : MCRL92298 Registration : 12/Mar/2024 02:22PM
UHID/MR No : ACRL.0000092298 Collected : 12/Mar/2024 02:17PM
Patient Name : Mr.AZHAR Received : 12/Mar/2024 02:47PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 12/Mar/2024 03:22PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM D Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135798

DEPARTMENT OF IMMUNOASSAY
Test Name Result Unit Bio. Ref. Range Method

Follicle Stimulating Hormone (FSH) 26.13 mlU/mL Please see below. Chemiluminescence
Immunoassay (CLIA)

Comment :
Follicle Stimulating Hormone (FSH) regulates the development, growth, pubertal maturation, and reproductive processes of the
human body. In both males and females, FSH stimulates the maturation of germ cells In males, FSH induces Sertoli cells to secrete
androgen binding proteins (ABPs) and its secretion is being regulated by inhibin's negative feedback mechanism on anterior
pituitary gland. In females, FSH initiates follicular growth, specifically affecting granulosa cells. With the concomitant rise in inhibin
B, FSH levels then decline in the late follicular phase. This seems to be critical in selecting only the most advanced follicle to
proceed to ovulation. At the end of the luteal phase, there is a slight rise in FSH that seems to be of importance to start the next
ovulatory cycle.
Control of FSH release from the pituitary gland is unknown. Low frequency gonadotropin-releasing hormone (GnRH) pulses
increase FSH mRNA levels in the rat, however this doesn't directly correlate with an increase in circulating FSH. GnRH has been
shown to play an important role in the secretion of FSH, with hypothalamic-pituitary disconection leading to a cessation of FSH.
GnRH administration leads to a return of FSH secretion. FSH is subject to oestrogen feed-back from the gonads via the
hypothalamic pituitary gonadal axis.

For Male 1.27 – 19.26 (mlU/mL)

PREMENOPAUSAL
Mid-Follicular Phase: 3.85- 8.78 mlU/mL
Mid-Cycle Peak 4.54-22.51 mlU/mL
Mid-Luteal Phase 1.79-5.12 mlU/mL
POSTMENOPAUSAL 16.74- 113.59 mlU/mL

QR CODE Page 3 of 4
Visit ID : MCRL92298 Registration : 12/Mar/2024 02:22PM
UHID/MR No : ACRL.0000092298 Collected : 12/Mar/2024 02:17PM
Patient Name : Mr.AZHAR Received : 12/Mar/2024 02:47PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 12/Mar/2024 03:22PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM D Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135798

DEPARTMENT OF IMMUNOASSAY
Test Name Result Unit Bio. Ref. Range Method

LH (leutinizing Hormone) 21.80 mIU/mL Follicular Phase: 1.7-15.0 Chemiluminescence

~Mid Cycle Peak: 21.9-56.6 Immunoassay (CLIA)
~Luteal Phase: 0.6-16.3
~Post Menopausal: 14.2-52.3
~Pregnant:<1.0-1.5
~Contraceptives:0.7-5.6

Comment
Luteinizing Hormone (LH) is a hormone produced by gonadotroph cells in the anterior pituitary gland. In females, an acute rise of
LH ("LH surge") triggers ovulation and development of the corpus luteum. LH supports theca cells in the ovaries that provide
androgens and hormonal precursors for estradiol production.

*** End Of Report ***

QR CODE Page 4 of 4
Visit ID : MCRL92722 Registration : 13/Mar/2024 02:35PM
UHID/MR No : ACRL.0000092722 Collected : 13/Mar/2024 02:29PM
Patient Name : Mr.AZHOR Received : 13/Mar/2024 09:48PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 15/Mar/2024 07:10PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM DIAG. Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135309

DEPARTMENT OF MICROBIOLOGY

TEST NAME : CULTURE URINE (AEROBIC 18 DRUGS)

SPECIMEN TYPE : URINE
SAMPLE TYPE URINE
ORGANISM ISOLATED ESCHERICHIA COLI
COLONY COUNT 10^5
CULTURE
Organism : Escherichia coli

ANTIBIOTIC SUSCEPTIBILITY
Organism : Escherichia coli
ANTIBIOTIC NAME INTERPRETATION
CEFUROXIME INTERMEDIATE SUSCEPTIBLE
COLISTIN INTERMEDIATE SUSCEPTIBLE
TETRACYCLINE INTERMEDIATE SUSCEPTIBLE
AMOXICILLIN RESISTANT
AMPICILLIN RESISTANT
CEFIXIME RESISTANT
CEFTAZIDIME RESISTANT
CEFTAZIDIME/AVIBACTAM RESISTANT
CIPROFLOXACIN RESISTANT
NALIDIXIC ACID RESISTANT
NITROFURANTOIN RESISTANT
NORFLOXACIN RESISTANT
AMIKACIN SUSCEPTIBLE
AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBLE
AMPICILLIN/SULBACTAM SUSCEPTIBLE
AZTREONAM SUSCEPTIBLE
CEFEPIME SUSCEPTIBLE
CEFEPIME-TAZOBACTAM SUSCEPTIBLE
CEFOPERAZONE/SULBACTAM SUSCEPTIBLE
CEFOTAXIME SUSCEPTIBLE
CEFTRIAXONE SUSCEPTIBLE
DORIPENEM SUSCEPTIBLE
ERTAPENEM SUSCEPTIBLE
GENTAMICIN SUSCEPTIBLE
IMIPENEM SUSCEPTIBLE
LEVOFLOXACIN SUSCEPTIBLE

Page 1 of 2
Visit ID : MCRL92722 Registration : 13/Mar/2024 02:35PM
UHID/MR No : ACRL.0000092722 Collected : 13/Mar/2024 02:29PM
Patient Name : Mr.AZHOR Received : 13/Mar/2024 09:48PM
Age/Gender : 35 Y 0 M 0 D /M Reported : 15/Mar/2024 07:10PM
Ref Doctor : Dr.SELF Status : Final Report
Client Name : PACIFIC PROMOTERS C/O SATYAM DIAG. Client Code : UP677LKO
Ref Customer : SELF Barcode No : B4135309

DEPARTMENT OF MICROBIOLOGY

MEROPENEM SUSCEPTIBLE
NETILMICIN SUSCEPTIBLE
OFLOXACIN SUSCEPTIBLE
PIPERACILLIN/TAZOBACTAM SUSCEPTIBLE
TIGECYCLINE SUSCEPTIBLE
TOBRAMYCIN SUSCEPTIBLE

Comment:
Growth Observed Clinical Significance
Bacterial Count of ≥105 org/mL Urinary tract Infection
Renal Transplant cases
Bacterial Count of 103 org/mL –105 org/mL Pregnancy
Urological Interventions
Kindly read in conjunction with the clinical status and history of the patient.
Always collect “clean catch midstream urine” in a sterile plastic container

Method: Conventional culture and sensitivity.

Kirby Bauer Disc diffusion Method as per CLSI Guidelines for Reporting Sensitivity.

*** End Of Report ***

Page 2 of 2